Chemotype-selective modes of action of κ-opioid receptor agonists.
about
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersSingle Amino Acid Variation Underlies Species-Specific Sensitivity to Amphibian Skin-Derived Opioid-like Peptides.Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activityStructure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid ReceptorSynthesis and κ-opioid receptor activity of furan-substituted salvinorin A analoguesA New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior.Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.Receptor Reserve Moderates Mesolimbic Responses to Opioids in a Humanized Mouse Model of the OPRM1 A118G PolymorphismOpioid receptors: Structural and mechanistic insights into pharmacology and signaling.NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptorStudies toward bivalent κ opioids derived from salvinorin A: heteromethylation of the furan ring reduces affinity.Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.The orexin 1 receptor modulates kappa opioid receptor function via a JNK-dependent mechanism.New Technologies for Elucidating Opioid Receptor Function.Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug designMichael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor.Identifying Functional Hotspot Residues for Biased Ligand Design in G-protein-coupled Receptors.Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands.
P2860
Q26748728-C9F1A4EB-B55F-4EF4-8DFB-117487D5D4C1Q27318592-23B906F7-FEA5-42D1-962A-2C024FEEC693Q28275440-6C9DD7D8-C614-45EE-B19F-E92F26FD1066Q33860286-9F12DDA5-8EAA-4495-910C-E776D9AC056FQ34796464-8B742F97-BE66-4224-A3A9-552C98F963E7Q35637848-0A00CADF-B088-452E-A9A8-D8E543D3D218Q35671396-DA89DAD4-6195-4D2D-BBE5-1C05BBF47D02Q36059914-B0AA965C-BBFD-447F-A171-90CB9459010EQ36096058-58419C36-FF14-4DC8-86A5-87345D0413D0Q36103013-AC1DB085-DB16-4CD6-A726-C6DB915DE6C2Q37495486-C8418081-C705-4C1B-9121-20226FEE5538Q38217456-F5C050C2-BB31-4647-BB03-81CC65700FB5Q38444486-7A7B4129-16D3-4FCD-9CC5-EF894E95A984Q38718788-9A5250F1-7014-49F2-94CD-CDDAC4E7048EQ39522869-1C233BBE-9639-4C31-A37D-7D21F9488063Q42141072-FAFF576A-532C-4199-9CF1-94DBDC5BABD5Q47558272-C8FB2314-C296-4F56-9777-ED9E1B662F91Q49789726-EEC844D8-4CE3-4C84-B3FB-5A9DC597EF49Q50591898-E5598512-A7D3-4402-8DDE-B19AB28FEF74
P2860
Chemotype-selective modes of action of κ-opioid receptor agonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotype-selective modes of action of κ-opioid receptor agonists.
@en
Chemotype-selective modes of action of κ-opioid receptor agonists.
@nl
type
label
Chemotype-selective modes of action of κ-opioid receptor agonists.
@en
Chemotype-selective modes of action of κ-opioid receptor agonists.
@nl
prefLabel
Chemotype-selective modes of action of κ-opioid receptor agonists.
@en
Chemotype-selective modes of action of κ-opioid receptor agonists.
@nl
P2093
P2860
P50
P356
P1476
Chemotype-selective modes of action of κ-opioid receptor agonists.
@en
P2093
Bryan L Roth
Eyal Vardy
Kevin J Frankowski
Philip D Mosier
Richard B Westkaemper
P2860
P304
34470-34483
P356
10.1074/JBC.M113.515668
P407
P577
2013-10-11T00:00:00Z